Dexcom: NEJM Study Redefining Standard of Care for People with Type 2 Diabetes Not on Insulin

 

• Publication marks the first time in nearly two decades that The New England Journal of Medicine has published clinical data on standalone real-time continuous glucose monitoring (CGM) technology, dating back to the creation of the CGM category.
• Randomized controlled trial demonstrates Dexcom G7 significantly reduces A1C and improves glucose control compared with routine care.
• Benefits observed across a broad range of participants, including those taking GLP-1 medications.¹
• Findings support the role of CGM earlier in Type 2 diabetes care for all people, including those over the age of 65.

https://investors.dexcom.com/news/news-details/2026/Landmark-Dexcom-CONNECT-Study-Published-in-The-New-England-Journal-of-Medicine-Redefining-the-Standard-of-Care-for-People-with-Type-2-Diabetes-Not-on-Insulin/default.aspx